Fatigue News and Research

RSS

Study: COVID-19 vaccines safe for IBD patients

Patients with inflammatory bowel diseases (IBD) do not appear to have increased risk of side effects from the Pfizer or Moderna COVID-19 vaccines, according to a recent Cedars-Sinai study published online and upcoming in print in the American Journal of Gastroenterology.

9 Jun 2021

Having trouble falling asleep associated with cognitive impairment 14 years later

A study of nearly 2,500 adults found that having trouble falling asleep, as compared to other patterns of insomnia, was the main insomnia symptom that predicted cognitive impairment 14 years later.

9 Jun 2021

COVID-19 projections after California's reopening

A new medrxiv* preprint shows how important equitable and widespread vaccination is in preventing a resurgence of cases and deaths once restrictions on social interactions are lifted.

8 Jun 2021

Antihistamines might be effective in long-COVID

A team of scientists from the United Kingdom has recently revealed the therapeutic benefits of histamine receptor antagonists in reducing long-term symptoms of coronavirus disease 2019 (COVID-19). They have also indicated that T cell immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection vary between asymptomatic COVID-19 and long-COVID.

8 Jun 2021

Are women more likely to develop long COVID?

Researchers found different groups of symptoms persisting after coronavirus disease 2019 (COVID-19), with fatigue and higher IL-6 levels common in women. About 75% of the patients they treated were women, indicating a link between sex hormones and immune response.

8 Jun 2021

New drug shows promise against lung cancer caused by genetic mutation

The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial.

8 Jun 2021

Repeated low-dose dose exposure to SARS-CoV-2 may protect against severe COVID-19

The Italian authors of this paper, published in the journal Viruses, have taken this hypothesis and expanded it to include viral particles suspended in the air or on inanimate objects as a possible source of T cell immunity due to the repeated low-dose exposure, potentially explaining virus immunity found in non-infected individuals.

7 Jun 2021

Around 5% of children develop long COVID-19 symptoms, suggests new study

A new study, by researchers at University College London (UCL) in the UK, shows that even though children rarely develop symptomatically severe COVID-19, the prevalence of long COVID in children with a history of infection is over 4.5%.

7 Jun 2021

Could sustained inflammation following mild to moderate COVID-19 be a driver of long COVID?

A new study describes the discovery of sustained though low-level rises in inflammatory mediators and immune cells, as well as the loss of some subsets of naïve un-activated cells. This may indicate a widespread though muted immune-mediated inflammatory response in these patients.

7 Jun 2021

New drug reduces tumor size in lung cancer patients who have a specific, disease-causing change

A new drug reduced tumor size in patients who have lung cancer with a specific, disease-causing change in the gene KRAS, a study found.

7 Jun 2021

COVID-19 symptoms in the feet

In a review paper recently uploaded to the Journal of Clinical Medicine by Jimenez-Cebrian et al. (May 19th, 2021), the clinical manifestations of COVID-19 in feet, in particular, are reviewed, finding that vascular, dermatological, and neurological symptoms have been widely reported.

6 Jun 2021

New treatment option offers disease control and extends life in patients with advanced prostate cancer

Cancer researchers say they have established a new, life-extending treatment option for men with prostate cancer that has spread and become resistant to hormone therapy.

5 Jun 2021

FDA approves new treatment for patients with hypoplasminogenemia

Today, the U.S. Food and Drug Administration approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with plasminogen deficiency type 1, also referred to as hypoplasminogenemia, a disorder that can impair normal tissue and organ function and may lead to blindness.

5 Jun 2021

Weight loss drug Wegovy approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Wegovy (semaglutide) injection (2.4 mg once weekly) as a chronic weight management treatment in obese or overweight adults with a weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), when used along with calorie restriction and physical activity. Wegovy, is a more potent version of Novo Nordisk's diabetes drug semaglutide.

4 Jun 2021

Post-COVID-19 assessment shows long-lasting consequences for many non-hospitalized individuals

Complications following COVID-19 infection require quick identification and management to help plan policy and health system responses. Researchers in the UK recently described the 12-month experience of the first dedicated post-COVID clinical service in the UK to include both hospitalized and non-hospitalized COVID-19 patients. This study has been released on the medRxiv* the preprint server.

4 Jun 2021